COPD

How to target high-risk populations with behavioral healthHere are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.
What providers need to do to improve chronic careA West survey finds that an overwhelming number of chronic care patients say they need help managing their disease.
Four ways tech improves chronic disease management
Four ways tech improves chronic disease managementFinding technology solutions to diagnose and manage chronic conditions is critical to the future of healthcare.
Effects of concurrent use of topical, oral beta blockersRecently, I received a progress note from a glaucoma surgeon concerning a patient whom he and I share. The patient is a 58-year-old African-American female with a longstanding history of primary open-angle glaucoma.
QD Fluticasone-Vilanterol combo reduces COPD exacerbationsIn patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events
Long-term safety of glycopyrrolate: A randomized study of COPD patientsGlycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
Dual therapy strategies for COPD: The scientific rationale for LAMA & LABAThere is a growing group of LAMA/LABA combination therapies in development. Investigations into the risks and benefits of LAMA/LABA therapy have demonstrated benefits.
Efficacy and safety of LABA/LAMA combinations in COPD: A network meta-analysisUpdate: LABA/LAMA combo therapies
COPD and pharmacotherapy for smoking cessation at the VA: StudyUse of tobacco-cessation therapy was low. The study found several negative factors — and two positive predictors.
Umeclidinium triple therapy for patients with COPD: Two studiesBoth studies demonstrated statistical improvements in trough FEV1 at day 85.